Rockefeller Capital Management L.P. Crispr Therapeutics Ag Transaction History

Rockefeller Capital Management L.P.

$38 Billion
Q1 2025

A detailed history of Rockefeller Capital Management L.P. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 90,503 shares of CRSP stock, worth $3.28 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

90,503

Previous 89,572 1.04%

Holding current value

$3.28 Million

Previous $3.53 Million 12.65%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$34.03 - $53.02 $31,681 - $49,361	931 Added 1.04%	90,503 $3.08 Million
Q4 2024 Feb 13, 2025	SELL	$38.65 - $55.15 $127,351 - $181,719	-3,295 Reduced 3.55%	89,572 $3.53 Million
Q3 2024 Nov 14, 2024	SELL	$44.62 - $62.75 $51,759 - $72,790	-1,160 Reduced 1.23%	92,867 $4.36 Million
Q2 2024 Aug 12, 2024	BUY	$51.17 - $68.18 $762,791 - $1.02 Million	14,907 Added 18.84%	94,027 $5.08 Million
Q1 2024 May 14, 2024	SELL	$60.67 - $89.12 $59,153 - $86,892	-975 Reduced 1.22%	79,120 $5.39 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $217,083 - $405,723	5,621 Added 7.55%	80,095 $5.01 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $41,577 - $54,044	916 Added 1.25%	74,474 $3.38 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $157,274 - $245,191	-3,618 Reduced 4.69%	73,558 $4.13 Million
Q1 2023 May 17, 2023	SELL	$41.0 - $56.12 $147,190 - $201,470	-3,590 Reduced 4.44%	77,176 $3.49 Million
Q4 2022 Mar 06, 2023	SELL	$39.19 - $65.67 $574,760 - $963,116	-14,666 Reduced 15.37%	80,766 $3.28 Million
Q3 2022 Nov 02, 2022	BUY	$61.1 - $83.78 $4.9 Million - $6.71 Million	80,146 Added 524.31%	95,432 $6.24 Million
Q2 2022 Aug 12, 2022	SELL	$43.23 - $73.83 $364,515 - $622,534	-8,432 Reduced 35.55%	15,286 $928,000
Q1 2022 May 13, 2022	BUY	$53.19 - $79.24 $2,978 - $4,437	56 Added 0.24%	23,718 $1.49 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $460,421 - $731,064	6,569 Added 38.43%	23,662 $1.79 Million
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $1.49 Million - $2.12 Million	13,550 Added 382.44%	17,093 $1.91 Million
Q2 2021 Aug 10, 2021	SELL	$100.84 - $161.89 $106,184 - $170,470	-1,053 Reduced 22.91%	3,543 $573,000
Q1 2021 May 11, 2021	SELL	$110.72 - $210.04 $137,514 - $260,869	-1,242 Reduced 21.27%	4,596 $560,000
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $105,244 - $228,836	1,321 Added 29.25%	5,838 $893,000
Q3 2020 Nov 13, 2020	BUY	$78.5 - $100.64 $62,957 - $80,713	802 Added 21.59%	4,517 $377,000
Q2 2020 Aug 12, 2020	BUY	$38.5 - $76.05 $77,000 - $152,100	2,000 Added 116.62%	3,715 $273,000
Q1 2020 May 12, 2020	SELL	$33.68 - $62.53 $4,445 - $8,253	-132 Reduced 7.15%	1,715 $72,000
Q4 2019 Feb 07, 2020	SELL	$36.68 - $73.13 $917 - $1,828	-25 Reduced 1.34%	1,847 $112,000
Q3 2019 Nov 12, 2019	SELL	$40.99 - $52.56 $4,385 - $5,623	-107 Reduced 5.41%	1,872 $77,000
Q2 2018 Jul 31, 2018	BUY	$42.62 - $73.59 $84,344 - $145,634	1,979 New	1,979 $116,000

Others Institutions Holding CRSP

# of Institutions

479

Shares Held

64.2M

Call Options Held

2.15M

Put Options Held

1.92M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $2.83B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.

Account

Rockefeller Capital Management L.P. Crispr Therapeutics Ag Transaction History